RAPT Therapeutics, Inc.
General ticker "RAPT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $519.6M (TTM average)
RAPT Therapeutics, Inc. follows the US Stock Market performance with the rate: 53.5%.
Estimated limits based on current volatility of 4.1%: low 32.69$, high 35.47$
Factors to consider:
- Total employees count: 68 (-48.1%) as of 2024
- Top business risk factors: Labor/talent shortage/retention, Geopolitical risks, Trade policy changes, Climate change and natural disasters, Operational and conduct risks
- Current price 129.3% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [6.50$, 20.86$]
- 2025-12-31 to 2026-12-31 estimated range: [4.86$, 15.31$]
Financial Metrics affecting the RAPT estimates:
- Positive: with PPE of -3.6 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -145.74 <= 0.04
- Positive: Shareholder equity ratio, % of 79.02 > 64.17
- Positive: Investing cash flow per share per price, % of 92.21 > -0.62
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term RAPT quotes
Long-term RAPT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1.53MM | $0.00MM | $0.00MM |
| Operating Expenses | $87.32MM | $127.06MM | $136.10MM |
| Operating Income | $-85.80MM | $-127.06MM | $-136.10MM |
| Non-Operating Income | $1.96MM | $10.26MM | $6.24MM |
| R&D Expense | $67.08MM | $101.00MM | $107.22MM |
| Income(Loss) | $-83.84MM | $-116.80MM | $-129.87MM |
| Profit(Loss)* | $-83.84MM | $-116.80MM | $-129.87MM |
| Stockholders Equity | $245.17MM | $147.03MM | $189.90MM |
| Assets | $266.21MM | $173.33MM | $240.32MM |
| Operating Cash Flow | $-70.77MM | $-97.05MM | $-83.30MM |
| Capital expenditure | $0.84MM | $1.12MM | $0.12MM |
| Investing Cash Flow | $-45.49MM | $104.13MM | $52.70MM |
| Financing Cash Flow | $131.18MM | $1.45MM | $152.85MM |
| Earnings Per Share** | $-20.61 | $-24.37 | $-25.49 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.